documents: FDA-2022-N-2390-0026

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2022-N-2390-0026 FDA FDA-2022-N-2390 Participation of Chief Counsel Mark Raza in re: Proposal to Refuse to Approve a New Drug Application Supplement for Hetlioz (Tasimelteon); Opportunity for a Hearing Other Memo 2023-08-30T04:00:00Z 2023 8 2023-08-30T04:00:00Z   2023-08-30T19:13:12Z   0 0 0900006485f14bbc

Links from other tables